Ayurvedic drug Femicycle as the first line of therapy for stressful menstrual disorders in women of reproductive age
Authors:   Odesa National Medical University, Ukraine, Nosenko O.M. , Suan Ni Din Tkhi ,   Odesa National Medical University, Ukraine
Published: October 2023

Purpose - to evaluate the effectiveness of the use of the Ayurvedic phytocomposition Femicycle for the correction of stressful menstrual disorders (MD) in women of reproductive age. Materials and methods. Under observation were 209 women aged 18 to 35 years, of which 177 with stressful MD (the Group I) and 32 gynecologically, mentally and somatically healthy women (the Group of the control (GC). All examined patients of the Group I received vitamin - mineral complexes. The Group I included the Main group (n=91), in which women additionally used the Ayurvedic drug Femicycle, 1 capsule twice a day with meals for 6 months. Patients in the Comparison group (n=86) received only vitamin and mineral complexes. The level of perception of stress according to PSS-10 and the level of psychological stress according to PSM-25, the hormonal profile of peripheral blood serum was assessed. MD were assessed before and after the treatment. Results. The level of perception of stress with the help of PSS-10 in the Group I was 1.57 times higher than in the GC - 34.91±0.56 points vs. 22.21±0.86 points (p<0.01). The level of psychological stress according to PSM-25 in the Group I was 1.28 times higher relative to this indicator in the GC, respectively - 114.61±0.97 points vs. 89.75±3.49 points (p<0.01). Compared to women in the GC, women with stress-induced disorders of the MC had a lower level of luteinizing hormone, increased levels of follicle-stimulating hormone, adrenocorticotropic hormone, thyroid-stimulating hormone against the background of decreased levels of estradiol, free testosterone, androstenedione, dehydroepiandrosterone sulfate and increased levels of cortisol and 17(OH)-progesterone. In patients of the Group I, after stress, the appearance of scanty menstruation was observed in 13.56% of cases, excessive menstruation - in 18.08%, rare menstruation - in 57.06%, amenorrhea - in 12.99% and intermenstrual bleeding - in 11.86%. In women of the Group I, 67.23% of cases had manifestations of dysmenorrhea and 48.59% of premenstrual syndrome vs. 37.50% (OR=3.084; 95% CI: 1.565-7.471) and 25.00% (OR=2.39; 95% CI: 1.209-6.651) individuals of the GC. After 6 months from the start of treatment, in the Main group, compared to the Comparative group, scarce menstruation was recorded 8.47 times less often (OR=2.073; 95% CI: 0.013-0.886), excessive menstruation - by 9.52 times (OR=2.209; 95% CI: 0.012-0.767), rare menstruation - 8.82 times (OR=3.297; 95% CI: 0.024-0.288), amenorrhea - 6.35 times (OR=1.750; 95% CI: 0.018-1.257]), intermenstrual bleeding - 3.70 times (OR=1.680; 95% CI: 0.051-1.254), dysmenorrhea - 1.72 times (OR=3.331; 95% CI: 0.193-0.653]), premenstrual syndrome - 1.71 times (OR=2.343; 95% CI: 0.239-0.880). Conclusions. Ayurvedic phytocomposition Femicycle is an effective remedy and first choice drug for women of reproductive age in the treatment of stressful MD. The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of the participating institution. No conflict of interests was declared by the authors.